Antibodies

  1. Schnellfilter:
  2. Zitierungen (10)

10 Artikel

pro Seite

Primärantikörper

Katalog-Nr. Wirt Iso. Klon Präs. Reakt. Anwendungen  

BETVIA allergen Bet v1 Antikörper

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG2 H.G27E9B1 Purified Pollen E, IP
0.1 mg / 600,00 €
  Dendritics SAS

BETVIA Antikörper

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG3 H.G26F6B2.06 Purified Pollen E
0.1 mg / 600,00 €
  Dendritics SAS

BETVIA Antikörper

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG4 H.G11A9F3.03 Purified Pollen E
0.1 mg / 600,00 €
  Dendritics SAS

BETVIA Antikörper

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG4 H.G28C10.01 Purified Pollen E
0.1 mg / 600,00 €
  Dendritics SAS

BETVIA Antikörper

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG1 H.G5F2A4.09 Purified Pollen E, WB
0.1 mg / 600,00 €
  Dendritics SAS

BETVIA Antikörper

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG2 H.G3A3C2.04 Purified Pollen E
0.1 mg / 600,00 €
  Dendritics SAS

BETVIA Antikörper

Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Mouse IgG4 H.G17E7A1 Purified Pollen E
0.1 mg / 600,00 €
  Dendritics SAS

Birch Pollen allergen Bet v1 Antikörper

Cross-reactivity with Bet v 1 homologous plant allergens Mouse IgG1 102H10.05 Purified Pollen NEUT
0.1 mg / 440,00 €
  Dendritics SAS

Birch Pollen allergen Bet v1 Antikörper

mAbs binding to nitrocellulose-blotted natural (n) or recombinant birch pollen Bet v 1 Mouse IgG1 110G10.01 Purified Pollen NEUT
0.1 mg / 440,00 €
  Dendritics SAS

Birch Pollen allergen Bet v1 Antikörper

Modulation of IgE (allergic patients) binding to Bet v 1 Mouse IgG1 202B8.03 Purified Pollen NEUT
0.1 mg / 440,00 €
  Dendritics SAS

10 Artikel

pro Seite
  • LinkedIn